Table 3.
Treatment outcomes by drug resistance category for the study cohort
| Drug resistance profile | Treatment outcomes | ||||
|---|---|---|---|---|---|
| Treatment success (%) | Loss from treatment (%) | Treatment failure (%) | Died (%) | Total | |
| R‐mono | 55 (55) | 35 (35) | 1 (1) | 10 (10) | 101 |
| MDR‐TB | 158 (51) | 99 (32) | 10 (3) | 42 (14) | 309 |
| Pre‐XDR (FLQ) | 3 (27) | 2 (18) | 3 (27) | 3 (27) | 11 |
| Pre‐XDR (INJ) | 7 (27) | 5 (19) | 3 (12) | 11 (42) | 26 |
| XDR‐TB | 5 (25) | 0 (0) | 4 (20) | 11 (55) | 20 |
| Total | 228 (49) | 141 (30) | 21 (4) | 77 (16) | 467 |
RIF‐mono, rifampicin mono‐resistance; MDR‐TB, multidrug‐resistant TB; Pre‐XDR (FLQ), MDR‐TB plus fluoroquinolone resistance; Pre‐XDR (INJ), MDR‐TB plus second‐line injectable resistance; XDR‐TB, extensively drug‐resistant TB.